Drugs / IASO104
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07185490 | Feb 2026 → Aug 2027 expected | plasma cell leukemia, refractory plasma cell neoplasm | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IASO104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07185490 ↗ |
| Modality | Cell therapy | “genetically modified autologous T-cell immunotherapy product” NCT07185490 ↗ |